Gyomor- és nyelőcsőrák: vizsgálatok itt: Törökország
15 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Where
- Adana, Ankara, Erzurum
- Életkor
- 18 év and over
- People
- 298 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00 - 3. fázisTaking peopleA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Where
- Adana, Ankara, Bursa, Istanbul, Konya, Samsun, Van
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00 - 2/3. fázisNot yet taking people in TörökországA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Where
- Ankara, Edirne, Kadiköy/Istanbul, Manisa, Sakarya
- Életkor
- 18 év and over
- People
- 690 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00 - 2. fázisVisszavonvaA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
- Where
- Adapazarı, Erzurum, Fatih-Istanbul, Istanbul
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07069712 · EU 2024-516909-23-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Ankara, Bağcılar, Izmir
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 3. fázisTaking peopleA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Where
- Ankara, Antalya, Diyarbakır, Erzurum, Istanbul, Izmir, Mezitli
- Életkor
- 18 év and over
- People
- 840 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00 - 3. fázisNot yet taking people in TörökországSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Where
- Ankara, Antalya, Istanbul, Medreseboğazı, Şahinbey
- Életkor
- 18 év and over
- People
- 2130 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00 - 3. fázisTaking peopleA Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- Adana, Ankara, Kuruköprü, Sefaköy
- Életkor
- 18 év and over
- People
- 351 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07043400 · EU 2025-522862-58-00 - 1/2. fázisTaking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Ankara, Istanbul, Yüreğir
- Életkor
- 18 év and over
- People
- 1438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - 1/2. fázisTaking peopleA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Where
- Adana, Ankara, Erzurum, Istanbul, Izmir
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05319730 · EU 2023-505189-26-00 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Ankara, Cordaleo, Edirne, Kadıkoy/Istanbul, Konya, Pamukkale, Samsun
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - No phaseNot yet taking people in TörökországFrailty, Immunonutrition, Surgery Type, and Biologic Recovery in Elderly Gastric Cancer
- Where
- Kocaeli
- Életkor
- 60 év and over
- People
- 328
- Run by
- Kocaeli City Hospital
See details and how to joinNCT07803159 - 3. fázisTaking peopleStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Where
- Adana, Ankara, Diyarbakır, Erzurum, Istanbul, Izmir, Samsun
- Életkor
- 18 év and over
- People
- 726 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06731478 - No phaseTaking peopleProximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer
- Where
- Istanbul
- Életkor
- 18 év to 90 év
- People
- 120
- Run by
- Nurettin Şahin
See details and how to joinNCT07482566 - 3. fázisTaking peopleA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Where
- Adana, Ankara, Diyarbakır, Edirne, Erzurum, Kayseri, Kocaeli, Sakarya, Tekirdağ
- Életkor
- 18 év and over
- People
- 550 worldwide
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06532006 · EU 2024-516633-12-00